Hosted on MSN

Cabaletta Bio Presents Promising RESET-PV Trial Data

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Cabaletta Bio ( (CABA)) has shared an ...
Frontiers

Integrated transcriptomic and single-cell RNA sequencing identifies lysosomal ion channel genes as potential biomarkers for Alzheimer’s disease

Alzheimer’s disease (AD), the most common neurodegenerative disorder, is characterized by progressive cognitive decline and neuropathological features, including amyloid-beta (Aβ) plaques and ...
Reuters

AI venture funding continued to surge in third quarter, data shows

Oct 6 (Reuters) - As the rush towards AI-related companies continues on Wall Street, data from Crunchbase showed on Monday that the sector enjoyed a bulk of venture funding in the third quarter, with ...
Hosted on MSN

Bio-Rad Laboratories Mourns Loss of Co-Founder Alice Schwartz

Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest update is out from Bio-Rad ...
BioSpace

Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug’s Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European ...

– Data support the potential of verekitug’s unique mechanism of action to achieve a differentiated therapeutic effect across a broad range of TSLP-driven severe respiratory diseases – WALTHAM, Mass., ...
Business Insider

Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN

New preclinical data demonstrate deeper IgA reduction and a longer half-life compared to first-generation anti-APRIL monoclonal antibody CLYM116 Phase 1 trial initiation expected in Q4 2025, with ...
https//beincrypto.com

1 CFX to KRW Calculator - How much South korean won (KRW) is 1 CRYPTOFOREX (CFX)?

Insights, news and analysis of the crypto market straight to your inbox ...
BioSpace

SystImmune, Inc. to Present New Clinical Data on Izalontamab Brengitecan and BL-M07D1 Highlighting Strength of Differentiated Antibody Drug Conjugate (ADC) Platform

REDMOND, Wash., Sept. 24, 2025 /PRNewswire/ -- SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced the presentation of data on iza-bren (izalontamab brengitecan) and ...